B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...

Epigenetic drugs boost CD20/CD19 and T-cell activity, making bispecific antibodies hit lymphoma harder—now moving into ...

Researchers from Shanghai Institute of Biological Products Co. Ltd. published details on the development and preclinical characterization of novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 ...

A new study shows how the single-molecule organization of receptors in a cellular context determines the function of antibodies, opening up new pathways for the development of cancer immunotherapies.